Caribou Biosciences, Inc. (CRBU) stock
Close on Nov 12, 2026Market cap $40.76MP/E –Yield –
Caribou Biosciences, Inc. grew revenue 1.6% to $9.44M over the twelve months to Sep 30, 2026. Free cash flow was -$92.99M. At the latest close the market valued the company at $40.76M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $40.76M
- P/E ratio
- –
- Price to sales
- 4.32
- Price to book
- 0.53
- Dividend yield
- –
- Free cash flow yield
- -228.14%
Fundamentals
- Revenue
- $9.44M
- Net income
- -$102.47M
- EPS, diluted
- -$1.03
- Free cash flow
- -$92.99M
- Book value per share
- $0.71
- Diluted shares
- 108M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $0.39
- Open
- $0.39
- Day's range
- $0.36 – $0.39
- Volume
- 1,539,713
- Average volume (20 days)
- 2,338,889
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.95
- 52-week range
- $0.36 – $2.49
- RSI (14 days)
- 26.7
- Volatility (1 year)
- 84.0%
- Relative volume
- 0.65×
- WACC
- 14.7%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRBU | S&P 500 | Difference | CRBU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | -2.7% | −20.8 pts | ||
| 3 months | -77.6% | -1.7% | −75.9 pts | ||
| Year to date | -76.1% | +11.9% | −88.0 pts | ||
| 1 year | -83.2% | +12.0% | −95.2 pts | ||
| 3 years | -90.1% | +78.2% | −168.3 pts | -53.8% | +21.2% |
| 5 years | -98.2% | +73.2% | −171.5 pts | -55.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Caribou Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Results
About Caribou Biosciences
Biological Products, (No Diagnostic Substances)
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited cell therapies for patients with devastating diseases. Utilizing its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology, the company engineers allogeneic, off-the-shelf chimeric antigen receptor (CAR)-T cell therapies designed to enhance precision and overcome the limitations of autologous cell therapies. Its clinical development pipeline features product candidates targeting hematologic malignancies, primarily vispacabtagene regedleucel (vispa-cel) for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. The therapies are aimed at patients suffering from severe blood cancers who require accessible and prompt cellular interventions.
Company profile, executives and historyCaribou Biosciences stock: common questions
What is Caribou Biosciences's stock price?
CRBU closed at $0.38 on Nov 12, 2026, down 2.69% on the day. Over the past 52 weeks it traded between $0.36 and $2.49.
What is Caribou Biosciences's market cap?
Caribou Biosciences was worth $40.76M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CRBU's P/E ratio?
Caribou Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.03), so it has no meaningful P/E ratio.
How much revenue does Caribou Biosciences make?
Caribou Biosciences reported revenue of $9.44M for the twelve months to Sep 30, 2026, up 1.6% from a year earlier.
Does Caribou Biosciences pay a dividend?
No. Caribou Biosciences has not paid a cash dividend over the last twelve months.
When does Caribou Biosciences report earnings next?
Caribou Biosciences is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CRBU stock performed over the past year?
Including dividends, CRBU returned -83.2% over the past year, against +12.0% for the S&P 500.
How many CRBU shares are sold short?
15M shares were sold short at the latest FINRA report, 14.72% of the float, or 6.0 days of average trading volume.
Who are Caribou Biosciences's competitors?
Companies most similar to Caribou Biosciences by business, industry and size include TCRX, CRSP, RLAY, XFOR, LCTX.
See a number that looks wrong?